Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2003-08-01
2009-06-23
Badio, Barbara P (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S814000, C552S642000, C552S643000, C552S648000
Reexamination Certificate
active
07550451
ABSTRACT:
The invention relates to new compounds of general formula I,their production and pharmaceutical preparations that contain these compounds.The compounds according to the invention are preferably used for female birth control and for HRT.
REFERENCES:
patent: 4257948 (1981-03-01), Costerousse et al.
patent: 4536401 (1985-08-01), Neef et al.
patent: 5089635 (1992-02-01), Neef et al.
patent: 5693628 (1997-12-01), Schubert et al.
patent: 6365582 (2002-04-01), Schubert et al.
patent: 6825182 (2004-11-01), Ring et al.
patent: 35 04 421 (1986-08-01), None
patent: 10221034 (2003-05-01), None
patent: 0005100 (1979-10-01), None
patent: 648 779 (1995-04-01), None
patent: WO 99/45023 (1999-09-01), None
patent: WO 01/15679 (2001-03-01), None
patent: WO 01/26603 (2001-04-01), None
patent: WO 01/34126 (2001-05-01), None
D. Loutradis et al., “Preovulatory effects of the progesterone antagonist mifepristone (RU486) in mice,” Human Reproduction, 1991, vol. 6, No. 9, pp. 1238-1240.
K. Chwalisz et al., “Antiproliferative effects of progesterone antagonists and progesterone receptor modulators on the endometrium,” Steroids, 2000, vol. 65, pp. 741-751.
O.D. Slayden et al., “Reversible suppression of menustration with progesterone antagonists in rhesus macaques,” Human Reproduction, 2001, vol. 16, No. 8, pp. 1562-1574.
W. Elger et al., “Endocrine pharmacological characterization of progesterone antagonists and progesterone receptor modulators with respect to PR-agonistic and antagonistic activity,” Steroids, 2000, vol. 65, pp. 713-723.
W. Elger et al., “Sulfamates of various estrogens are prodrugs with increased systemic and reduced hepatic estrogenicity at oral application,” J. Steroid Biochem. Molec. Biol., 1995, vol. 55, No. ¾, pp. 395-403.
E. M. Coutinho et al., “Is Menstruation Obsolete?” 1999, New York, Oxford University Press.
E.Isaksson et al., “Effects of oral contraceptives on breast epithelial proliferation,” Breast Cancer Research and Treatment, 2001, vol. 65, pp. 163-169.
A. J. Spiegel et al., “Use of nonaqueous solvents in parenteral products,” Journal of Pharmaceutical Sciences, Oct. 1963. vol. 52, No. 10, pp. 917-927.
Louis J. Ravin, “Preformulation,” Bioavailability and Bioequivalency Testing, Chapter 75, pp. 1355-1497.
Dwight L. Deardorff, “Ophtalmic Preparations,” Medicated Applications, Chapter 86, pp. 1498-1628.
G. Teutsch et al., 11Beta-substituted steroids, an original pathway to antihormones, 1988, vol. 31, No. 4B, pp. 549-565.
Xiang-Shu Fei et al., “New, convenient route four trifluoromethylation of steroidal molecules,” J. Chem. Soc., Perkin Trans. 1, 1998, pp. 1139-1142.
Roussel-Uclaf, Bulletin Official de la Propriete Industrielle, No. 30.
Pharmazeutische Technologie, 1961, Jahrgang 23 (Heft 2).
Arzneimittel, Synthetische s. Chemotherapie und Pharmakotherapeutica,Ullmann's Encyclopedia of Technical Chemistry, vol. 4, 1953.
International Search Report, PCT/EP03/08572, 2003.
Elger Walter
Hillisch Alexander
Reddersen Gudrun
Schneider Birgitt
Schubert Gerd
Badio Barbara P
Bayer Schering Pharma AG
Millen White Zelano & Branigan P.C.
LandOfFree
Progesterone receptor modulators with increased... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Progesterone receptor modulators with increased..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Progesterone receptor modulators with increased... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4148152